Literature DB >> 21186097

Pre-morbid Conduct Disorder symptoms are associated with cannabis use among individuals with a first episode of psychosis.

Charlotte P Malcolm1, Marco M Picchioni, Marta DiForti, Gisela Sugranyes, Elizabeth Cooke, Candice Joseph, Grant McQueen, Alessandra Paparelli, Simona Stilo, Jennifer O'Connor, Craig Morgan, Robin M Murray, Sheilagh Hodgins.   

Abstract

BACKGROUND: Early cannabis use has consistently been associated with an increased risk for the later development of psychosis. Studies suggest that Conduct Disorder (CD) is more common amongst young people who later go on to develop psychosis. CD has been associated with greater and earlier cannabis use in general population samples. Based on this evidence, we hypothesised that among patients experiencing their first episode of psychosis, the presence of CD symptoms prior to age 15 would be associated with cannabis use.
METHOD: 102 patients experiencing a first episode of psychosis were interviewed to assess CD symptoms prior to age 15 and use of cannabis and other substances.
RESULTS: The number of CD symptoms was significantly associated with lifetime cannabis use (odds ratio=5.41 (1.76-16.57), p=0.03) and with first use of cannabis before age 14 (odds ratio=1.46 (1.12-1.92), p=0.006), after controlling for stimulant/hallucinogen use and level of education.
CONCLUSIONS: Among patients experiencing a first episode of psychosis, CD symptoms were significantly associated with use of cannabis and with use by age 14. Among individuals vulnerable for psychosis, CD symptoms may independently increase the likelihood of cannabis use which in turn increases the risk of psychosis.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21186097     DOI: 10.1016/j.schres.2010.11.025

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  8 in total

Review 1.  New Clinically Relevant Findings about Violence by People with Schizophrenia.

Authors:  Sheilagh Hodgins; Sanja Klein
Journal:  Can J Psychiatry       Date:  2016-07-11       Impact factor: 4.356

Review 2.  [Schizophrenia and violence].

Authors:  S Hodgins; R Müller-Isberner
Journal:  Nervenarzt       Date:  2014-03       Impact factor: 1.214

3.  Structural brain alterations associated with schizophrenia preceded by conduct disorder: a common and distinct subtype of schizophrenia?

Authors:  Boris Schiffer; Norbert Leygraf; Bernhard W Müller; Norbert Scherbaum; Michael Forsting; Jens Wiltfang; Elke R Gizewski; Sheilagh Hodgins
Journal:  Schizophr Bull       Date:  2012-09-26       Impact factor: 9.306

Review 4.  Aggressive Behavior Among Persons With Schizophrenia and Those Who Are Developing Schizophrenia: Attempting to Understand the Limited Evidence on Causality.

Authors:  Sheilagh Hodgins
Journal:  Schizophr Bull       Date:  2017-09-01       Impact factor: 9.306

Review 5.  Psychotic disorders comorbid with attention-deficit hyperactivity disorder: an important knowledge gap.

Authors:  Emmanuelle Levy; Alexandru Traicu; Srividya Iyer; Ashok Malla; Ridha Joober
Journal:  Can J Psychiatry       Date:  2015-03       Impact factor: 4.356

Review 6.  Could Expanding and Investing in First-Episode Psychosis Services Prevent Aggressive Behaviour and Violent Crime?

Authors:  Sheilagh Hodgins
Journal:  Front Psychiatry       Date:  2022-02-15       Impact factor: 4.157

7.  Prevalence of bullying victimisation amongst first-episode psychosis patients and unaffected controls.

Authors:  Antonella Trotta; Marta Di Forti; Valeria Mondelli; Paola Dazzan; Carmine Pariante; Anthony David; Alice Mulè; Laura Ferraro; Ivan Formica; Robin M Murray; Helen L Fisher
Journal:  Schizophr Res       Date:  2013-07-26       Impact factor: 4.939

8.  Associations between the schizophrenia susceptibility gene ZNF804A and clinical outcomes in psychosis.

Authors:  A Wickramasinghe; A D Tulloch; R D Hayes; C-K Chang; M Broadbent; M Di Forti; R M Murray; C Iyegbe; R Stewart
Journal:  Transl Psychiatry       Date:  2015-12-15       Impact factor: 6.222

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.